FibroBiologics, Inc. SEC filings FBLG
FibroBiologics, Inc. has 242 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form ARS, was filed on May 5, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (material agreement, new debt, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 19, 2026 | — |
| EFFECT | Filing | Oct 19, 2026 | — |
| POS AM | Filing | Oct 13, 2026 | — |
| POS AM | Filing | Oct 13, 2026 | — |
| D | Filing | Oct 13, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 8, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 18, 2026 | Sep 17, 2026 |
| D | Filing | Sep 16, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 15, 2026 | Sep 15, 2026 |
| DEFA14A | Additional proxy material | Sep 9, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 24, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| DEF 14A | Proxy statement | Jul 31, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 24, 2026 | Jul 22, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 17, 2026 | Sep 17, 2026 |
| EFFECT | Filing | Jul 16, 2026 | — |
| 424B3 | Prospectus | Jul 16, 2026 | — |
| S-3 | Shelf registration | Jul 10, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 9, 2026 | Jul 2, 2026 |
| D | Filing | Jun 29, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 29, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Material agreement
|
May 6, 2026 | May 5, 2026 |
| 424B5 | Prospectus supplement | May 6, 2026 | — |
| 8-K |
Current report
Officer or director change
|
May 5, 2026 | May 4, 2026 |
| ARS | Annual report to shareholders | May 5, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | May 5, 2026 | — |
| DEF 14A | Proxy statement | May 5, 2026 | May 5, 2026 |
| 424B5 | Prospectus supplement | May 1, 2026 | — |
| 8-K |
Current report
Material agreement
|
May 1, 2026 | May 1, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 22, 2026 | Apr 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 20, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 17, 2026 | Apr 16, 2026 |
| 8-K/A |
Amended current report
Material agreement, Agreement ended, Other events
|
Apr 9, 2026 | Apr 3, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 9, 2026 | Apr 3, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Apr 3, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Apr 2, 2026 | Mar 31, 2026 |
| 424B4 | Prospectus | Apr 1, 2026 | — |
| EFFECT | Filing | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| S-1 | Registration statement | Mar 27, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2026 | — |
| DRS | Filing | Mar 20, 2026 | — |
| 10-K/A | Amended annual report | Mar 13, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 6, 2026 | Mar 4, 2026 |
| 10-K | Annual report | Feb 24, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Feb 23, 2026 | Feb 20, 2026 |
| 8-K |
Current report
Listing notice
|
Feb 6, 2026 | Feb 3, 2026 |
| 8-K |
Current report
Listing notice
|
Jan 2, 2026 | Dec 30, 2025 |
| EFFECT | Filing | Dec 30, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 29, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2025 | — |
| DEFA14A | Additional proxy material | Dec 29, 2025 | — |
| DEF 14A | Proxy statement | Dec 29, 2025 | Feb 20, 2026 |
| S-1 | Registration statement | Dec 23, 2025 | — |
| PRE 14A | Preliminary proxy statement | Dec 18, 2025 | Dec 18, 2025 |
| DEF 14A | Proxy statement | Dec 18, 2025 | Dec 18, 2025 |
| D | Filing | Dec 16, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 15, 2025 | Dec 14, 2025 |
| 424B5 | Prospectus supplement | Dec 15, 2025 | — |
| D | Filing | Dec 3, 2025 | — |
| D | Filing | Dec 3, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 25, 2025 | Nov 24, 2025 |
| 424B5 | Prospectus supplement | Nov 25, 2025 | — |
| 424B5 | Prospectus supplement | Nov 20, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Nov 19, 2025 | Nov 18, 2025 |
| 10-Q | Quarterly report | Oct 31, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 8, 2025 | Aug 4, 2025 |
| 10-Q | Quarterly report | Jul 31, 2025 | Jun 30, 2025 |
| 8-K/A |
Amended current report
Unregistered share sale
|
Jul 18, 2025 | Dec 20, 2024 |
| 8-K |
Current report
Unregistered share sale
|
Jul 18, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 3, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jun 16, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 13, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 9, 2025 | Jun 9, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Officer or director change
|
May 5, 2025 | May 2, 2025 |
| ARS | Annual report to shareholders | Apr 23, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Feb 10, 2025 | — |
| 8-K |
Current report
Unregistered share sale
|
Feb 7, 2025 | Jan 7, 2025 |
| CORRESP | Letter to the SEC | Feb 6, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2025 | — |
| S-3 | Shelf registration | Feb 3, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Jan 24, 2025 | Jan 23, 2025 |
| EFFECT | Filing | Jan 21, 2025 | — |
| POS AM | Filing | Jan 17, 2025 | — |
| EFFECT | Filing | Jan 14, 2025 | — |
| 424B4 | Prospectus | Jan 14, 2025 | — |
| S-1/A | Amended registration statement | Jan 10, 2025 | — |
| CORRESP | Letter to the SEC | Jan 10, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2025 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Dec 31, 2024 | Dec 27, 2024 |
| S-1 | Registration statement | Dec 30, 2024 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Dec 23, 2024 | Dec 20, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Dec 20, 2024 | Dec 19, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 29, 2024 | Oct 25, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 24, 2024 | Sep 19, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 28, 2024 | Aug 27, 2024 |
| 8-K |
Current report
Unregistered share sale, Regulation FD disclosure
|
Aug 27, 2024 | Aug 26, 2024 |
| EFFECT | Filing | Aug 14, 2024 | — |
| POS AM | Filing | Aug 13, 2024 | — |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| ARS | Annual report to shareholders | Jul 8, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Jul 8, 2024 | — |
| DEF 14A | Proxy statement | Jul 8, 2024 | Jul 8, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 27, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 27, 2024 | Jun 25, 2024 |
| 424B4 | Prospectus | Jun 26, 2024 | — |
| EFFECT | Filing | Jun 25, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| CORRESP | Letter to the SEC | Jun 18, 2024 | — |
| S-1 | Registration statement | Jun 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2024 | — |
| DRS | Filing | Jun 10, 2024 | — |
| RW | Filing | Jun 6, 2024 | — |
| S-1/A | Amended registration statement | Jun 4, 2024 | — |
| S-1/A | Amended registration statement | May 15, 2024 | — |
| S-8 | Employee stock plan registration | May 15, 2024 | — |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Other events
|
Apr 26, 2024 | Apr 26, 2024 |
| S-1 | Registration statement | Apr 26, 2024 | — |
| DRS | Filing | Apr 12, 2024 | — |
| EFFECT | Filing | Mar 28, 2024 | — |
| 424B4 | Prospectus | Mar 28, 2024 | — |
| CORRESP | Letter to the SEC | Mar 27, 2024 | — |
| S-1/A | Amended registration statement | Mar 26, 2024 | — |
| CORRESP | Letter to the SEC | Mar 26, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2024 | — |
| S-1/A | Amended registration statement | Mar 15, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| 10-K | Annual report | Feb 29, 2024 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Feb 26, 2024 | — |
| 8-K |
Current report
Other events
|
Feb 20, 2024 | Feb 20, 2024 |
| 8-K |
Current report
Other events
|
Feb 14, 2024 | Feb 13, 2024 |
| S-1 | Registration statement | Feb 12, 2024 | — |
| 8-K |
Current report
Other events
|
Feb 8, 2024 | Feb 8, 2024 |
| 8-K |
Current report
Other events
|
Feb 6, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Other events
|
Feb 2, 2024 | Jan 31, 2024 |
| 424B4 | Prospectus | Jan 31, 2024 | — |
| CERT | Filing | Jan 30, 2024 | — |
| EFFECT | Filing | Jan 24, 2024 | — |
| S-1/A | Amended registration statement | Jan 24, 2024 | — |
| 8-A12B | Filing | Jan 24, 2024 | — |
| S-1/A | Amended registration statement | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| S-1/A | Amended registration statement | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| S-1/A | Amended registration statement | Jan 12, 2024 | — |
| FWP | Free writing prospectus | Dec 14, 2023 | — |
| S-1/A | Amended registration statement | Dec 7, 2023 | — |
| S-1/A | Amended registration statement | Dec 4, 2023 | — |
| S-1/A | Amended registration statement | Nov 30, 2023 | — |
| S-1/A | Amended registration statement | Nov 28, 2023 | — |
| CORRESP | Letter to the SEC | Nov 7, 2023 | — |
| S-1 | Registration statement | Nov 7, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2023 | — |
| DRSLTR | Filing | Oct 13, 2023 | — |
| DRS/A | Filing | Oct 13, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2023 | — |
| DRSLTR | Filing | Aug 16, 2023 | — |
| DRS/A | Filing | Aug 16, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2023 | — |
| DRS | Filing | May 18, 2023 | — |
| C-AR | Filing | May 1, 2023 | Dec 31, 2022 |
| C-U | Filing | Apr 11, 2023 | — |
| C/A | Filing | Mar 29, 2023 | — |
| C/A | Filing | Feb 10, 2023 | — |
| C | Filing | Jan 31, 2023 | — |
Showing 177 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBLG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1958777
- Former names
- FibroBiologics Inc. (until Feb 6, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.